EHMT2 and cancer: In summary, this paper highlights a previously unrecognized therapeutic vulnerability of neuroblastomas with MYCN amplification to small molecule inhibitors of G9a, As MYCN is also a known driver of several other cancers, this work underlines the need for future work on these cancers with current inhibitors, and the development of next generation G9a inhibitors.